A groundbreaking new drug, Kisunla, also known as donanemab, has received FDA approval for the treatment of Alzheimer’s disease, offering hope to the Alzheimer’s community. This drug has the potential to reduce cognitive decline in patients by 35%. Developed by Lilly, the drug is administered through infusion once a month, with the treatment stopping when a patient’s brain is clear of beta-amyloid plaques that are associated with the disease.
Dr. Howard Fillit, a prominent figure in the field of Alzheimer’s treatment advancements, emphasized the significance of this breakthrough, marking a long-awaited confirmation of the role of beta-amyloid protein in the disease process. Patients will undergo PET scans to monitor the recurrence of plaques in the brain, allowing for personalized treatment and potential remission.
While the exact cost of Kisunla is yet to be determined, the drug is expected to become more accessible as it is not a lifelong treatment. The FDA approval of the drug has been met with optimism by the Alzheimer’s community, with hopes for additional treatments to further reduce the impact of the disease. The Alzheimer’s Foundation of America and other experts have highlighted the importance of continued research and support for individuals suffering from Alzheimer’s.
Overall, the approval of Kisunla represents a significant step forward in the treatment of Alzheimer’s disease, offering a glimmer of hope for those affected by this devastating condition. The drug is poised to make a positive difference in the lives of patients and their families, ushering in a new era of treatment options for Alzheimer’s.
Source
Photo credit www.wishtv.com